Breast cancer growth prevention by statins.

Breast cancer growth prevention by statins. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Breast cancer growth prevention by statins. Abstract Text:

Michael J Campbell,Laura J Esserman,Yamei Zhou,Mark Shoemaker,Margaret Lobo,Elizabeth Borman,Frederick Baehner,Anjali S Kumar,Kelly Adduci,Corina Marx,Emanuel F Petricoin,Lance A Liotta,Mary Winters,Stephen Benz,Christopher C Benz,

Statins are cholesterol-lowering drugs with pleiotropic activities including inhibition of isoprenylation reactions and reduction of signals driving cell proliferation and survival responses. The objectives of this study were to examine the effects of statins on breast cancer cells, both in vitro and in vivo, and to begin to determine their mechanism of action. We evaluated the effects of statins on breast cancer cell growth, phosphoprotein signaling intermediates, survival/apoptosis regulators, cell cycle regulators, and activated transcription factors. We also examined the in vivo effect of statin administration in a mouse ErbB2(+) breast cancer model. Only lipophilic statins had direct anticancer activity in vitro. Breast cancer cells with activated Ras or ErbB2 pathways seemed to be more sensitive than those overexpressing estrogen receptor, and this correlated with endogenous levels of activated nuclear factor kappaB (NF-kappaB). Key intermediates regulating cell survival by NF-kappaB activation, as well as cell proliferation by the mitogen activated protein kinase cascade, were among the earliest phosphoproteins influenced by statin treatment. These early effects were followed by declines in activator protein-1 and NF-kappaB activation and concordant changes in other mediators of proliferation and apoptosis. In vivo results showed that oral dosing of statins significantly inhibited the growth of a mouse mammary carcinoma. Lipophilic statins can exert direct anticancer activity in vitro by reducing proliferation and survival signals in susceptible breast cancer phenotypes. Tumor growth inhibition in vivo using a clinically relevant statin dose also seems to be associated with reduced tumor cell proliferation and survival. These findings provide supporting rationale for future statin trials in breast cancer patients.

Breast cancer growth prevention by statins. Publishing Authors By Initials

MJ Campbell,LJ Esserman,Y Zhou,M Shoemaker,M Lobo,E Borman,F Baehner,AS Kumar,K Adduci,C Marx,EF Petricoin,LA Liotta,M Winters,S Benz,CC Benz,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Breast cancer growth prevention by statins. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer research

VOLUME: 66

Page Numbers: 8707-14

Journal Abbreviation:

ISSN: 1538-7445

DAY: 1

MONTH: Sep

YEAR: 2006

Breast cancer growth prevention by statins. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Breast cancer growth prevention by statins. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Breast cancer growth prevention by statins. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Breast cancer growth prevention by statins.

AFFILIATION: Department of Surgery, University of California San Francisco/Mt. Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115, USA. campbellm@surgery.ucsf.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Breast cancer growth prevention by statins Related Publications

• Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
• Anti-oncomir suppression of tumor phenotypes.
• Breast cancer growth prevention by statins.
• Characterization of channel-forming activity in muscle biopsy from a porin-deficient human patient.
• Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.
• Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.
• Corynebacterium diphtheriae: identification and characterization of a channel-forming protein in the cell wall.
• Development of an Integrated Approach to Cancer Disparities: One Cancer Center's Experience.
• Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
• Evaluation of the rate constants of sugar transport through maltoporin (LamB) of Escherichia coli from the sugar-induced current noise.
• LamB (maltoporin) of Salmonella typhimurium: isolation, purification and comparison of sugar binding with LamB of Escherichia coli.
• MANIFESTATIONS OF THE ROSS RIVER AND BARMAH FOREST ARBOVIRUSES: A Clinical Challenge for Chiropractors.
• Noise analysis of ion current through the open and the sugar-induced closed state of the LamB channel of Escherichia coli outer membrane: evaluation of the sugar binding kinetics to the channel interior.
• Of alternate and designated IACUC members. Regulations trump convenience.
• PH-induced collapse of the extracellular loops closes Escherichia coli maltoporin and allows the study of asymmetric sugar binding.
• PNEUMONIA FROM A PUBLIC HEALTH VIEW POINT.
• Pneumonia Quarantine.
• Pore formation by the Bordetella adenylate cyclase toxin in lipid bilayer membranes: Role of voltage and pH.
• Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
• Rate constants of sugar transport through two LamB mutants of Escherichia coli: comparison with wild-type maltoporin and LamB of Salmonella typhimurium.
• Regulated Fox-2 isoform expression mediates protein 4.1R splicing during erythroid differentiation.
• Site-directed mutagenesis of tyrosine 118 within the central constriction site of the LamB (Maltoporin) channel of Escherichia coli. I. Effect on ion transport.
• Site-directed mutagenesis of tyrosine 118 within the central constriction site of the LamB (maltoporin) channel of Escherichia coli. II. Effect on maltose and maltooligosaccharide binding kinetics.
• Site-directed mutagenesis within the central constriction site of ScrY (sucroseporin): effect on ion transport and comparison of maltooligosaccharide binding to LamB of Escherichia coli.
• The administration of enemas to infants and children.
• The deletion of 70 amino acids near the N-terminal end of the sucrose-specific porin ScrY causes its functional similarity to LamB in vivo and in vitro.
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]